Non-hallucinogenic versions of drugs like LSD, psilocybin and MDMA could unlock their potential in mental illness.

After >20 years of research at the intersection of virology and immunology, two brothers have launched a venture seeking to turn arenaviruses into an anticancer virotherapy.

Recent patents relating to epigenomic analyses, modification and engineering.

A quarterly snapshot of job expansions, reductions and availability in the biotech and pharma sectors.

Patients need the patent system to spur the investment necessary for the continued development of life-saving diagnostics and therapies.

Recent moves of note in and around the biotech and pharma industries.

The elusive HER3, known to drive aggressive cancers, may finally be toppled by once-abandoned antibody drugs.

mRNA printers will bring low-cost vaccines and made-to-order treatments for a range of different diseases.

In the ascendant world of mRNA medicines, circular RNA shows promise as an alternative way for making proteins inside human cells.

The biotech sector must devote more resources to cybersecurity — especially those companies that are manufacturers of essential medical products.

Recent moves of note in and around the biotech and pharma industries.

Companies are deploying siRNA and antisense oligonucleotides to tackle dangerously high cholesterol driven by genetics, betting that a wider population will benefit.

Recent patents relating to checkpoint inhibitors and their use in treating cancers.

Companies pursue souped-up IL-2 candidates, undeterred by Nektar’s setback.

The digitalization of R&D can potentially transform the life sciences, but it cannot succeed without experts collaborating to develop a vision of what a better working environment can look like.

After over a decade of experience with immune checkpoint inhibitors in oncology, more effort needs to be spent unraveling why some patients respond — and why the majority do not — and integrating knowledge about biomarkers into patient selection in trials.